司美格鲁肽前三季度收入超200亿美元,诺和诺德下调年度营收增长上限

澎湃新闻
06 Nov 2024

诺和诺德三季报再次让医药行业看到司美格鲁肽这款明星产品的市场潜力。  11月6日,丹麦制药企业诺和诺德公布2024年三季报。单季度来看,诺和诺德第三季度收入713.11亿丹麦克朗,同比增长22%,净利润273.01亿丹麦克朗,同比增长21%,高于市场预期。或受上述消息影响,11月6日美股盘前,诺和诺德最高涨超6%。   诺和诺德前三季度业绩  前三季度整体来看,诺和诺德收入2047.2亿丹麦克朗,...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10